Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide

Detalhes bibliográficos
Autor(a) principal: Pereira, Rosa Maria Rodrigues
Data de Publicação: 2012
Outros Autores: Carvalho, Jozélio Freire de, Paula, Ana Patrícia, Zerbini, Cristiano Augusto de Freitas, Domiciano, Diogo Souza, Gonçalves, Helenice, Danowski, Jaime S., Marques Neto, João Francisco, Mendonça, Laura Maria Carvalho, Bezerra, Mailze Campos, Terreri, Maria Teresa Ramos Ascensão [UNIFESP], Imamura, Marta, Weingrill, Pedro, Plapler, Perola Grinberg, Radominski, Sebastião, Tourinho, Tatiana, Szejnfeld, Vera Lucia [UNIFESP], Andrada, Nathalia Carvalho de
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S0482-50042012000400009
http://repositorio.unifesp.br/handle/11600/7239
Resumo: Glucocorticoids (GC) are used in almost all medical specialties, and approximately 0.5% of the general population of the United Kingdom receives those medications. With the increased survival of patients with rheumatological diseases, morbidity secondary to the use of those medications represents an important aspect of the management of our patients. The incidences of vertebral and non-vertebral fractures are elevated, ranging from 30% to 50% of the individuals on GC for over three months. Thus, osteoporosis and frailty fractures should be prevented and treated in all patients initiating or already on GC. There are several recommendations on this topic elaborated by several international societies, but consensus still lacks. Recently, the American College of Rheumatology has published new recommendations, but they are based on the WHO Fracture Risk Assessment Tool (FRAX®) to evaluate the risk for each individual, and, thus, cannot be completely used for the Brazilian population. Thus, the Committee for Osteoporosis and Bone Metabolic Disorders of the Brazilian Society of Rheumatology, along with the Brazilian Medical Association and the Brazilian Association of Physical Medicine and Rehabilitation, has elaborated the Brazilian Guidelines for Glucocorticoid-Induced Osteoporosis (GIO), based on the better available scientific evidence and/or expert experience. METHOD OF EVIDENCE COLLECTION: The bibliographic review of scientific articles of this guideline was performed in the MEDLINE database. The search for evidence was based on real clinical scenarios, and used the following keywords (MeSH terms): Osteoporosis, Osteoporosis/ chemically induced*= (Glucocorticoids= Adrenal Cortex Hormones, Steroids), Glucocorticoids, Glucocorticoids/administration and dosage, Glucocorticoids/therapeutic use, Glucocorticoids/adverse effects, Prednisone/adverse effects, Dose-Response Relationship, Drug, Bone Density/drug effects, Bone Density Conservation Agents/pharmacological action, Osteoporosis/prevention & control, Calcium, Vitamin D, Vitamin D deficiency, Calcitriol, Receptors, Calcitriol; 1-hydroxycholecalciferol, Hydroxycholecalciferols, 25-Hydroxyvitamin D3 1-alpha-hydroxylase OR Steroid Hydroxylases, Prevention and Control, Spinal fractures/prevention & control, Fractures, Spontaneous, Lumbar Vertebrae/injuries, Lifestyle, Alcohol Drinking, Smoking OR tobacco use disorder, Movement, Resistance Training, Exercise Therapy, Bone density OR Bone and Bones, Dual-Energy X-Ray Absorptiometry OR Absorptiometry Photon OR DXA, Densitometry, Radiography, (Diphosphonates Alendronate OR Risedronate Pamidronate OR propanolamines OR Ibandronate OR Zoledronic acid, Teriparatide OR PTH 1-34, Men AND premenopause, pregnancy, pregnancy outcome maternal, fetus, lactation, breast-feeding, teratogens, Children (6-12 years), adolescence (13-18 years). GRADE OF RECOMMENDATION AND LEVEL OF EVIDENCE: A) Data derived from more consistent experimental and observational studies; B) Data derived from less consistent experimental and observational studies; C) Case reports (uncontrolled studies); D) Expert opinion without explicit critical appraisal, or based on consensus, physiological studies or animal models. OBJECTIVE: To establish guidelines for the prevention and treatment of GIO.
id UFSP_c01a0950efda4dead4fefa71e03a3281
oai_identifier_str oai:repositorio.unifesp.br/:11600/7239
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoideGuidelines for the prevention and treatment of glucocorticoid-induced osteoporosistreatmentosteoporosisglucocorticoidtratamentoosteoporoseglicocorticoideGlucocorticoids (GC) are used in almost all medical specialties, and approximately 0.5% of the general population of the United Kingdom receives those medications. With the increased survival of patients with rheumatological diseases, morbidity secondary to the use of those medications represents an important aspect of the management of our patients. The incidences of vertebral and non-vertebral fractures are elevated, ranging from 30% to 50% of the individuals on GC for over three months. Thus, osteoporosis and frailty fractures should be prevented and treated in all patients initiating or already on GC. There are several recommendations on this topic elaborated by several international societies, but consensus still lacks. Recently, the American College of Rheumatology has published new recommendations, but they are based on the WHO Fracture Risk Assessment Tool (FRAX®) to evaluate the risk for each individual, and, thus, cannot be completely used for the Brazilian population. Thus, the Committee for Osteoporosis and Bone Metabolic Disorders of the Brazilian Society of Rheumatology, along with the Brazilian Medical Association and the Brazilian Association of Physical Medicine and Rehabilitation, has elaborated the Brazilian Guidelines for Glucocorticoid-Induced Osteoporosis (GIO), based on the better available scientific evidence and/or expert experience. METHOD OF EVIDENCE COLLECTION: The bibliographic review of scientific articles of this guideline was performed in the MEDLINE database. The search for evidence was based on real clinical scenarios, and used the following keywords (MeSH terms): Osteoporosis, Osteoporosis/ chemically induced*= (Glucocorticoids= Adrenal Cortex Hormones, Steroids), Glucocorticoids, Glucocorticoids/administration and dosage, Glucocorticoids/therapeutic use, Glucocorticoids/adverse effects, Prednisone/adverse effects, Dose-Response Relationship, Drug, Bone Density/drug effects, Bone Density Conservation Agents/pharmacological action, Osteoporosis/prevention & control, Calcium, Vitamin D, Vitamin D deficiency, Calcitriol, Receptors, Calcitriol; 1-hydroxycholecalciferol, Hydroxycholecalciferols, 25-Hydroxyvitamin D3 1-alpha-hydroxylase OR Steroid Hydroxylases, Prevention and Control, Spinal fractures/prevention & control, Fractures, Spontaneous, Lumbar Vertebrae/injuries, Lifestyle, Alcohol Drinking, Smoking OR tobacco use disorder, Movement, Resistance Training, Exercise Therapy, Bone density OR Bone and Bones, Dual-Energy X-Ray Absorptiometry OR Absorptiometry Photon OR DXA, Densitometry, Radiography, (Diphosphonates Alendronate OR Risedronate Pamidronate OR propanolamines OR Ibandronate OR Zoledronic acid, Teriparatide OR PTH 1-34, Men AND premenopause, pregnancy, pregnancy outcome maternal, fetus, lactation, breast-feeding, teratogens, Children (6-12 years), adolescence (13-18 years). GRADE OF RECOMMENDATION AND LEVEL OF EVIDENCE: A) Data derived from more consistent experimental and observational studies; B) Data derived from less consistent experimental and observational studies; C) Case reports (uncontrolled studies); D) Expert opinion without explicit critical appraisal, or based on consensus, physiological studies or animal models. OBJECTIVE: To establish guidelines for the prevention and treatment of GIO.Os glicocorticoides (GC) são prescritos por praticamente todas as especialidades médicas, e cerca de 0,5% da população geral do Reino Unido utiliza esses medicamentos. Com o aumento da sobrevida dos pacientes com doenças reumatológicas, a morbidade secundária ao uso dessa medicação representa um aspecto importante que deve ser considerado no manejo de nossos pacientes. As incidências de fraturas vertebrais e não vertebrais são elevadas, variando de 30%-50% em pessoas que usam GC por mais de três meses. Assim, a osteoporose e as fraturas por fragilidade devem ser prevenidas e tratadas em todos os pacientes que iniciarão ou que já estejam em uso desses esteroides. Diversas recomendações elaboradas por várias sociedades internacionais têm sido descritas na literatura, porém não há consenso entre elas. Recentemente, o Americam College of Rheumatology publicou novas recomendações, porém elas são fundamentadas na FRAX (WHO Fracture Risk Assessment Tool) para analisar o risco de cada indivíduo e, dessa maneira, não podem ser completamente utilizadas pela população brasileira. Dessa forma, a Comissão de Osteoporose e Doenças Osteometabólicas da Sociedade Brasileira de Reumatologia, em conjunto com a Associação Médica Brasileira e a Associação Brasileira de Medicina Física e Reabilitação, implementou as diretrizes brasileiras de osteoporose induzida por glicocorticoide (OPIG), baseando-se na melhor evidência científica disponível e/ou experiência de experts. DESCRIÇÃO DO MÉTODO DE COLETA DE EVIDÊNCIA: A revisão bibliográfica de artigos científicos desta diretriz foi realizada na base de dados MEDLINE. A busca de evidência partiu de cenários clínicos reais, e utilizou as seguintes palavras-chave (MeSH terms): Osteoporosis, Osteoporosis/chemically induced*= (Glucocorticoids= Adrenal Cortex Hormones, Steroids), Glucocorticoids, Glucocorticoids/administration and dosage, Glucocorticoids/therapeutic use, Glucocorticoids/adverse effects, Prednisone/adverse effects, Dose-Response Relationship, Drug, Bone Density/drug effects, Bone Density Conservation Agents/pharmacological action, Osteoporosis/ prevention&control, Calcium, Vitamin D, Vitamin D deficiency, Calcitriol, Receptors, Calcitriol; 1-hydroxycholecalciferol, Hydroxycholecalciferols, 25-Hydroxyvitamin D3 1-alpha-hydroxylase OR Steroid Hydroxylases, Prevention and Control, Spinal fractures/prevention & control, Fractures, Spontaneous, Lumbar Vertebrae/injuries, Lifestyle, Alcohol Drinking, Smoking OR tobacco use disorder, Movement, Resistance Training, Exercise Therapy, Bone density OR Bone and Bones, Dual-Energy X-Ray Absorptiometry OR Absorptiometry Photon OR DXA, Densitometry, Radiography, (Diphosphonates Alendronate OR Risedronate Pamidronate OR propanolamines OR Ibandronate OR Zoledronic acid, Teriparatide OR PTH 1-34, Men AND premenopause, pregnancy, pregnancy outcome maternal, fetus, lactation, breast-feeding, teratogens, Children (6-12 anos), adolescence (13-18 anos). GRAU DE RECOMENDAÇÃO E FORÇA DE EVIDÊNCIA: A) Estudos experimentais e observacionais de melhor consistência; B) Estudos experimentais e observacionais de menor consistência; C) Relatos de casos (estudos não controlados); D) Opinião desprovida de avaliação crítica, com base em consensos, estudos fisiológicos ou modelos animais. OBJETIVO: Estabelecer as diretrizes para a prevenção e o tratamento da OPIG.Universidade de São Paulo Faculdade de MedicinaUniversidade Federal da Bahia Hospital Universitário Serviço de ReumatologiaUniversidade de Brasília Faculdade de Ciências da Saúde Programa de Pós-graduaçãoHospital HeliópolisUniversidade Federal de Santa CatarinaUSP FM Hospital das ClínicasAssociação Médica de BrasíliaHospital Israelita Albert SabinUniversidade Estadual de CampinasPontifícia Universidade Católica de CampinasUniversidade Federal do Rio de JaneiroHospital Geral de FortalezaUniversidade de FortalezaAlbert-Ludwigs Universität FreiburgUSP FM Departamento de PediatriaUSP FM HCUniversidade de Joinville Faculdade de MedicinaUSP FM Departamento de Ortopedia e TraumatologiaHospital do CoraçãoUniversidade Federal do ParanáUniversidade Federal de Ciências da Saúde de Porto AlegreUniversidade Federal de São Paulo (UNIFESP)Associação Médica BrasileiraUNIFESP, EPM, São Paulo, BrazilSciELOSociedade Brasileira de ReumatologiaUniversidade de São Paulo (USP)Universidade Federal da Bahia Hospital Universitário Serviço de ReumatologiaUniversidade de Brasília Faculdade de Ciências da Saúde Programa de Pós-graduaçãoHospital HeliópolisUniversidade Federal de Santa CatarinaAssociação Médica de BrasíliaHospital Israelita Albert SabinUniversidade Estadual de Campinas (UNICAMP)Pontifícia Universidade Católica de CampinasUniversidade Federal do Rio de JaneiroHospital Geral de FortalezaUniversidade de FortalezaAlbert-Ludwigs Universität FreiburgUniversidade de Joinville Faculdade de MedicinaHospital do CoraçãoUniversidade Federal do ParanáUniversidade Federal de Ciências da Saúde de Porto AlegreUniversidade Federal de São Paulo (UNIFESP)Associação Médica BrasileiraPereira, Rosa Maria RodriguesCarvalho, Jozélio Freire dePaula, Ana PatríciaZerbini, Cristiano Augusto de FreitasDomiciano, Diogo SouzaGonçalves, HeleniceDanowski, Jaime S.Marques Neto, João FranciscoMendonça, Laura Maria CarvalhoBezerra, Mailze CamposTerreri, Maria Teresa Ramos Ascensão [UNIFESP]Imamura, MartaWeingrill, PedroPlapler, Perola GrinbergRadominski, SebastiãoTourinho, TatianaSzejnfeld, Vera Lucia [UNIFESP]Andrada, Nathalia Carvalho de2015-06-14T13:44:52Z2015-06-14T13:44:52Z2012-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion580-593application/pdfhttp://dx.doi.org/10.1590/S0482-50042012000400009Revista Brasileira de Reumatologia. Sociedade Brasileira de Reumatologia, v. 52, n. 4, p. 580-593, 2012.10.1590/S0482-50042012000400009S0482-50042012000400009.pdf0482-5004S0482-50042012000400009http://repositorio.unifesp.br/handle/11600/7239porRevista Brasileira de Reumatologiainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-29T23:07:17Zoai:repositorio.unifesp.br/:11600/7239Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-07-29T23:07:17Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis
title Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
spellingShingle Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
Pereira, Rosa Maria Rodrigues
treatment
osteoporosis
glucocorticoid
tratamento
osteoporose
glicocorticoide
title_short Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
title_full Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
title_fullStr Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
title_full_unstemmed Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
title_sort Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
author Pereira, Rosa Maria Rodrigues
author_facet Pereira, Rosa Maria Rodrigues
Carvalho, Jozélio Freire de
Paula, Ana Patrícia
Zerbini, Cristiano Augusto de Freitas
Domiciano, Diogo Souza
Gonçalves, Helenice
Danowski, Jaime S.
Marques Neto, João Francisco
Mendonça, Laura Maria Carvalho
Bezerra, Mailze Campos
Terreri, Maria Teresa Ramos Ascensão [UNIFESP]
Imamura, Marta
Weingrill, Pedro
Plapler, Perola Grinberg
Radominski, Sebastião
Tourinho, Tatiana
Szejnfeld, Vera Lucia [UNIFESP]
Andrada, Nathalia Carvalho de
author_role author
author2 Carvalho, Jozélio Freire de
Paula, Ana Patrícia
Zerbini, Cristiano Augusto de Freitas
Domiciano, Diogo Souza
Gonçalves, Helenice
Danowski, Jaime S.
Marques Neto, João Francisco
Mendonça, Laura Maria Carvalho
Bezerra, Mailze Campos
Terreri, Maria Teresa Ramos Ascensão [UNIFESP]
Imamura, Marta
Weingrill, Pedro
Plapler, Perola Grinberg
Radominski, Sebastião
Tourinho, Tatiana
Szejnfeld, Vera Lucia [UNIFESP]
Andrada, Nathalia Carvalho de
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade de São Paulo (USP)
Universidade Federal da Bahia Hospital Universitário Serviço de Reumatologia
Universidade de Brasília Faculdade de Ciências da Saúde Programa de Pós-graduação
Hospital Heliópolis
Universidade Federal de Santa Catarina
Associação Médica de Brasília
Hospital Israelita Albert Sabin
Universidade Estadual de Campinas (UNICAMP)
Pontifícia Universidade Católica de Campinas
Universidade Federal do Rio de Janeiro
Hospital Geral de Fortaleza
Universidade de Fortaleza
Albert-Ludwigs Universität Freiburg
Universidade de Joinville Faculdade de Medicina
Hospital do Coração
Universidade Federal do Paraná
Universidade Federal de Ciências da Saúde de Porto Alegre
Universidade Federal de São Paulo (UNIFESP)
Associação Médica Brasileira
dc.contributor.author.fl_str_mv Pereira, Rosa Maria Rodrigues
Carvalho, Jozélio Freire de
Paula, Ana Patrícia
Zerbini, Cristiano Augusto de Freitas
Domiciano, Diogo Souza
Gonçalves, Helenice
Danowski, Jaime S.
Marques Neto, João Francisco
Mendonça, Laura Maria Carvalho
Bezerra, Mailze Campos
Terreri, Maria Teresa Ramos Ascensão [UNIFESP]
Imamura, Marta
Weingrill, Pedro
Plapler, Perola Grinberg
Radominski, Sebastião
Tourinho, Tatiana
Szejnfeld, Vera Lucia [UNIFESP]
Andrada, Nathalia Carvalho de
dc.subject.por.fl_str_mv treatment
osteoporosis
glucocorticoid
tratamento
osteoporose
glicocorticoide
topic treatment
osteoporosis
glucocorticoid
tratamento
osteoporose
glicocorticoide
description Glucocorticoids (GC) are used in almost all medical specialties, and approximately 0.5% of the general population of the United Kingdom receives those medications. With the increased survival of patients with rheumatological diseases, morbidity secondary to the use of those medications represents an important aspect of the management of our patients. The incidences of vertebral and non-vertebral fractures are elevated, ranging from 30% to 50% of the individuals on GC for over three months. Thus, osteoporosis and frailty fractures should be prevented and treated in all patients initiating or already on GC. There are several recommendations on this topic elaborated by several international societies, but consensus still lacks. Recently, the American College of Rheumatology has published new recommendations, but they are based on the WHO Fracture Risk Assessment Tool (FRAX®) to evaluate the risk for each individual, and, thus, cannot be completely used for the Brazilian population. Thus, the Committee for Osteoporosis and Bone Metabolic Disorders of the Brazilian Society of Rheumatology, along with the Brazilian Medical Association and the Brazilian Association of Physical Medicine and Rehabilitation, has elaborated the Brazilian Guidelines for Glucocorticoid-Induced Osteoporosis (GIO), based on the better available scientific evidence and/or expert experience. METHOD OF EVIDENCE COLLECTION: The bibliographic review of scientific articles of this guideline was performed in the MEDLINE database. The search for evidence was based on real clinical scenarios, and used the following keywords (MeSH terms): Osteoporosis, Osteoporosis/ chemically induced*= (Glucocorticoids= Adrenal Cortex Hormones, Steroids), Glucocorticoids, Glucocorticoids/administration and dosage, Glucocorticoids/therapeutic use, Glucocorticoids/adverse effects, Prednisone/adverse effects, Dose-Response Relationship, Drug, Bone Density/drug effects, Bone Density Conservation Agents/pharmacological action, Osteoporosis/prevention & control, Calcium, Vitamin D, Vitamin D deficiency, Calcitriol, Receptors, Calcitriol; 1-hydroxycholecalciferol, Hydroxycholecalciferols, 25-Hydroxyvitamin D3 1-alpha-hydroxylase OR Steroid Hydroxylases, Prevention and Control, Spinal fractures/prevention & control, Fractures, Spontaneous, Lumbar Vertebrae/injuries, Lifestyle, Alcohol Drinking, Smoking OR tobacco use disorder, Movement, Resistance Training, Exercise Therapy, Bone density OR Bone and Bones, Dual-Energy X-Ray Absorptiometry OR Absorptiometry Photon OR DXA, Densitometry, Radiography, (Diphosphonates Alendronate OR Risedronate Pamidronate OR propanolamines OR Ibandronate OR Zoledronic acid, Teriparatide OR PTH 1-34, Men AND premenopause, pregnancy, pregnancy outcome maternal, fetus, lactation, breast-feeding, teratogens, Children (6-12 years), adolescence (13-18 years). GRADE OF RECOMMENDATION AND LEVEL OF EVIDENCE: A) Data derived from more consistent experimental and observational studies; B) Data derived from less consistent experimental and observational studies; C) Case reports (uncontrolled studies); D) Expert opinion without explicit critical appraisal, or based on consensus, physiological studies or animal models. OBJECTIVE: To establish guidelines for the prevention and treatment of GIO.
publishDate 2012
dc.date.none.fl_str_mv 2012-08-01
2015-06-14T13:44:52Z
2015-06-14T13:44:52Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S0482-50042012000400009
Revista Brasileira de Reumatologia. Sociedade Brasileira de Reumatologia, v. 52, n. 4, p. 580-593, 2012.
10.1590/S0482-50042012000400009
S0482-50042012000400009.pdf
0482-5004
S0482-50042012000400009
http://repositorio.unifesp.br/handle/11600/7239
url http://dx.doi.org/10.1590/S0482-50042012000400009
http://repositorio.unifesp.br/handle/11600/7239
identifier_str_mv Revista Brasileira de Reumatologia. Sociedade Brasileira de Reumatologia, v. 52, n. 4, p. 580-593, 2012.
10.1590/S0482-50042012000400009
S0482-50042012000400009.pdf
0482-5004
S0482-50042012000400009
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Revista Brasileira de Reumatologia
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 580-593
application/pdf
dc.publisher.none.fl_str_mv Sociedade Brasileira de Reumatologia
publisher.none.fl_str_mv Sociedade Brasileira de Reumatologia
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268330668720128